• 提示：詳情請(qǐng)下載說(shuō)明書(shū)。

• 產(chǎn)品描述： BMS202 (PD-1/PD-L1 inhibitor 2)是一種抑制PD-1/PD-L1相互作用的小分子化合物，IC50為18 nM

• 靶點(diǎn)： PD-1/PD-L1 interaction(Cell-free assay):0.018 μM;Apoptosis;PD-1/PD-L1

• 體外研究：
  BMS-202 inhibits PD-1/PD-L1 binding in SCC-3 and Jurkat cells with IC50 of 15 μM and 10 μM, respectively.

• 體內(nèi)研究：
  BMS-202 treatment shows a clear antitumor effect compared with the controls, in humanized MHC- dKO NOG mice.

• 細(xì)胞實(shí)驗(yàn)： Cell lines: SCC-3 and Jurkat cells Concentrations: IC50 of 15 μM and 10 μM Incubation Time: 4 days Method: Cells were treated with various concentrations of drug for 4 days.

• 動(dòng)物實(shí)驗(yàn)： Animal Models: NOG-dKO mice Dosages: 20 mg/kg Administration: i.p.

• 參考文獻(xiàn)：
  1. (WO2015034820), COMPOUNDS USEFUL AS IMMUNOMODULATORS. 2. Krzysztof M. Zak, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016, 7(21): 30323–30335. 3. Ashizawa T, et al. Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. Biomed Res. 2019;40(6):243-250.

• 溶解性： Soluble  in  DMSO、Ethanol

• 保存條件： -20℃

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	2.384 ml	11.918 ml	23.837 ml
  5 mM	0.477 ml	2.384 ml	4.767 ml
  10 mM	0.238 ml	1.192 ml	2.384 ml
  50 mM	0.048 ml	0.238 ml	0.477 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *